Biogen touts ‘resilience’ but gives little guidance on Alzheimer's drug

Biogen’s CEO Michel Vounatsos painted the drugmaker as a resilient fighter during a year-end investor call Thursday, while laying out the strategy for several major crusades that lie ahead.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.